港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

宜明昂科-B

6.440

+0.0500.78%

成交量：104.04万

成交额：668.31万

市值：26.21亿

市盈率：-7.16

高：6.520

开：6.360

低：6.270

收：6.390

数据加载中...

总览公司新闻资讯公告

财通证券：增肌治疗需求扩大建议关注宜明昂科(01541)等

宜明昂科-B股价重挫15.02% 市值跌3.21亿港元

宜明昂科(01541.HK)IMC-003/IMM72临床试验申请获受理

阿斯达克财经

宜明昂科-B(01541)获国家药监局受理IMC-003/IMM72治疗肺动脉高压(PAH)的临床试验的申请

每日卖空追踪 | 宜明昂科-B 04月02日卖空量成交1.86万股，卖空比例为0.28%

宜明昂科-B04月01日主力净流入675万元散户资金抛售

宜明昂科－Ｂ(01541)股价大幅上升21.918%，现价港币$7.12

阿斯达克财经

港股异动 | 医药股早盘走强国内创新药逐渐进入收获期市场预期集采政策优化

异动解读 | 宜明昂科-B盘中大涨19.52%，年度收入激增192倍

异动解读 | 宜明昂科-B盘中大涨19.52%，年收入暴增192倍

港股异动 | 宜明昂科-B(01541)早盘涨超18% 全年收入同比增长192倍机构称公司目前价值严重低估

宜明昂科-B：核心管线稳步推进积极拓展BD合作

太平洋证券

宜明昂科-B03月27日获主力加仓4万元

港股异动 | 宜明昂科-B(01541)午前涨超3% 年度收入大增至7414.9万元研发开支持续加码

异动解读 | 宜明昂科-B盘中大涨6.17%，董事长增持15万股提振市场信心

宜明昂科(01541.HK)董事长兼CEO增持15万股涉79万元

阿斯达克财经

宜明昂科-B(01541)获首席执行官田文志增持15万股H股

异动解读 | 宜明昂科-B盘中大跌5.17%，年度业绩亏损仍超3亿元

异动解读 | 宜明昂科-B盘中大涨5.17%，2024年营收暴增191倍

宜明昂科2024年业绩：收入增至7414.9万元年内亏损降至3.17亿元

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/01541/news?page=3"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"01541","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01541\",,,,,undefined,":{"symbol":"01541","market":"HK","secType":"STK","nameCN":"宜明昂科-B","latestPrice":6.44,"timestamp":1746778087029,"preClose":6.39,"halted":0,"volume":1040400,"delay":0,"floatShares":382000000,"shares":407000000,"eps":-0.8997257384310218,"marketStatus":"休市中","change":0.05,"latestTime":"05-09 16:08:07","open":6.36,"high":6.52,"low":6.27,"amount":6683087,"amplitude":0.039124,"askPrice":6.44,"askSize":11000,"bidPrice":6.38,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.8997257384310218,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1747013400000},"marketStatusCode":7,"adr":0,"listingDate":1693843200000,"exchange":"SEHK","adjPreClose":6.39,"openAndCloseTimeList":[[1746754200000,1746763200000],[1746766800000,1746777600000]],"volumeRatio":0.5488499683709158,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01541\",,,,,undefined,":{"symbol":"01541","floatShares":382000000,"roa":"-21.43%","roe":"-44.38%","lyrEps":-0.899726,"volumeRatio":0.5488499683709158,"shares":407000000,"dividePrice":0,"high":6.52,"amplitude":0.039124,"preClose":6.39,"low":6.27,"week52Low":3.21,"pbRate":"3.59","psRate":"30.67","week52High":22,"institutionHeld":0,"latestPrice":6.44,"committee":-0.964286,"eps":-0.8997257384310218,"divideRate":0,"volume":1040400,"delay":0,"ttmEps":-0.8997257384310218,"open":6.36,"prevYearClose":5.16,"prevWeekClose":6.37,"prevMonthClose":6.25,"prevQuarterClose":5.84,"fiveDayClose":6.25,"twentyDayClose":4.91,"sixtyDayClose":5.45},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"01541\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525035063","title":"财通证券：增肌治疗需求扩大 建议关注宜明昂科(01541)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2525035063","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525035063?lang=zh_cn&edition=fundamental","pubTime":"2025-04-07 14:04","pubTimestamp":1744005858,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，财通证券发布研报称，阻断激活素受体通路被临床用于治疗肌肉萎缩相关疾病。近年来GLP1RA类药物的广泛使用，目前的GLP-1RA疗法会带来使用者约25-40%肌肉流失，因此老龄人群和减重人群也存在较大的增肌治疗需求。建议关注国内布局相关资产的公司，如来凯医药-B、宜明昂科等。增肌治疗需求较大，市场空间广阔遗传性神经肌肉疾病患者、老龄人群和减重人群均存在较大增肌治疗需求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1274515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601108","BK1161","01541","BK0276"],"gpt_icon":0},{"id":"2525036801","title":"宜明昂科-B股价重挫15.02% 市值跌3.21亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2525036801","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525036801?lang=zh_cn&edition=fundamental","pubTime":"2025-04-07 09:30","pubTimestamp":1743989430,"startTime":"0","endTime":"0","summary":"2025年04月07日早盘09时30分，宜明昂科-B股票出现波动，股价急速下跌15.02%。截至发稿，该股报5.600港元/股，成交量11.5万股，换手率0.03%，振幅2.12%。资金方面，该股资金流入3.2492万港元，流出16.7896万港元。宜明昂科-B股票所在的生物技术行业中，整体跌幅为8.07%。其相关个股中，中生北控生物科技、正大企业国际、中国抗体-B涨幅较大，振幅较大的相关个股有加科思-B、复宏汉霖、和铂医药-B，振幅分别为9.70%、9.68%、7.95%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040709303194cd9a42&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040709303194cd9a42&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2524379413","title":"宜明昂科(01541.HK)IMC-003/IMM72临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2524379413","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524379413?lang=zh_cn&edition=fundamental","pubTime":"2025-04-02 23:33","pubTimestamp":1743607980,"startTime":"0","endTime":"0","summary":"宜明昂科－Ｂ(01541.HK) 公布，集团IMC-003/IMM72治疗肺动脉高压(PAH)的临床试验申请已获中国国家药监局受理。IMC-003/IMM72为通过基因改造的新一代启动素受体IIA-Fc型融合蛋白，具有更高的活性及品质。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-02 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230915102621607_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230915102621607_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1431406/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01541","BK1141","03347","BK1576","BK1583","BK1161"],"gpt_icon":0},{"id":"2524956494","title":"宜明昂科-B(01541)获国家药监局受理IMC-003/IMM72治疗肺动脉高压(PAH)的临床试验的申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2524956494","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524956494?lang=zh_cn&edition=fundamental","pubTime":"2025-04-02 22:02","pubTimestamp":1743602563,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B(01541)公布，中华人民共和国国家药品监督管理局(国家药监局)已受理集团IMC-003/IMM72治疗肺动脉高压(PAH)的临床试验的申请。这标志着集团在快速推进非肿瘤疾病的临床研究方面取得里程碑式的成就。IMC-003/IMM72为通过基因改造的新一代启动素受体IIA-Fc型(ActRIIA-Fc)融合蛋白，具有更高的活性及品质。该集团拥有IMC-003/IMM72的全球知识产权以及开发及商业化权利。截至本公告日期，就IMC-003/IMM72而言，该集团拥有一个专利家族，其中包括在中国、美国、日本及欧盟的已授权专利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1273550.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","BK1583","BK1576","03347","BK1141","BK1161"],"gpt_icon":0},{"id":"2524649754","title":"每日卖空追踪 | 宜明昂科-B 04月02日卖空量成交1.86万股，卖空比例为0.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2524649754","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524649754?lang=zh_cn&edition=fundamental","pubTime":"2025-04-02 19:11","pubTimestamp":1743592281,"startTime":"0","endTime":"0","summary":"宜明昂科-B北京时间04月02日，跌1.29%，卖空量成交1.86万股，较上一交易日减少86.96%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250402191126a6ad0c3e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250402191126a6ad0c3e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2524169399","title":"宜明昂科-B04月01日主力净流入675万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2524169399","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524169399?lang=zh_cn&edition=fundamental","pubTime":"2025-04-01 16:15","pubTimestamp":1743495308,"startTime":"0","endTime":"0","summary":"04月01日, 宜明昂科-B股价涨19.86%，报收7.00元，成交金额1.11亿元，换手率4.20%，振幅27.91%，量比4.89。宜明昂科-B今日主力资金（超大单+大单）净流入675万元，上一交易日主力净流出0万元。该股近5个交易日上涨28.23%，主力资金累计净流入691万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入264万元，其中净流入天数为8日。该股主力净额占比0.25%（主力资金净额/流通市值），港股市场排名28/2654。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250401165347a6aba919&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250401165347a6aba919&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2524155062","title":"宜明昂科－Ｂ(01541)股价大幅上升21.918%，现价港币$7.12","url":"https://stock-news.laohu8.com/highlight/detail?id=2524155062","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524155062?lang=zh_cn&edition=fundamental","pubTime":"2025-04-01 14:40","pubTimestamp":1743489600,"startTime":"0","endTime":"0","summary":"[上升股]宜明昂科－Ｂ(01541) 股价在下午02:40比前收市价大幅上升21.918%，现股价为港币$7.12。至目前为止，今日最高价为$7.5，而最低价为$5.87。总成交量为1.388千万股，总成交金额为港币$9.583千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2504013426/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2524056184","title":"港股异动 | 医药股早盘走强 国内创新药逐渐进入收获期 市场预期集采政策优化","url":"https://stock-news.laohu8.com/highlight/detail?id=2524056184","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524056184?lang=zh_cn&edition=fundamental","pubTime":"2025-04-01 10:20","pubTimestamp":1743474025,"startTime":"0","endTime":"0","summary":"消息面上，2025年医保谈判将于二季度拉开帷幕，从今年开始，医保药品目录调整时间会适当提前，预计从4月1日开始申报，争取9月份完成。民生证券表示，中国本土医药创新逐渐进入收获期，国际化进程持续加速，继续重点看好医药创新主线，同时医药板块基本面持续向上复苏，同时看好医药消费主线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1272383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","LU1794554557.SGD","BK1583","09995","LU0348784397.USD","LU1720050803.USD","09969","IE00BPRC5H50.USD","BK1574","06855","LU0417516571.SGD","09926","IE00B5MMRT66.SGD","159938","06978","LU0348783233.USD","LU2488822045.USD","LU1969619763.USD","LU2328871848.SGD","01541","09939","BK1515","IE00B543WZ88.USD","BK1161"],"gpt_icon":0},{"id":"1190377977","title":"异动解读 | 宜明昂科-B盘中大涨19.52%，年度收入激增192倍","url":"https://stock-news.laohu8.com/highlight/detail?id=1190377977","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190377977?lang=zh_cn&edition=fundamental","pubTime":"2025-04-01 10:12","pubTimestamp":1743473552,"startTime":"0","endTime":"0","summary":"宜明昂科-B今日盘中股价大涨19.52%，引发市场广泛关注。截至上午10点09分，该股报价6.93港元，成交额达2546.88万港元。此次股价飙升主要源于公司发布的亮眼年度业绩报告。宜明昂科-B全年实现总收入7,415万元，同比增长192倍，收入主要来自授权许可费和合作开发。国元国际分析师对宜明昂科-B给予积极评价。他们指出，基于公司CD47核心产品在肿瘤及自免领域的领先优势和广阔市场空间，目前22亿港元的市值严重低估了公司价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01541"],"gpt_icon":0},{"id":"1158405442","title":"异动解读 | 宜明昂科-B盘中大涨19.52%，年收入暴增192倍","url":"https://stock-news.laohu8.com/highlight/detail?id=1158405442","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158405442?lang=zh_cn&edition=fundamental","pubTime":"2025-04-01 10:12","pubTimestamp":1743473549,"startTime":"0","endTime":"0","summary":"宜明昂科-B今日盘中大涨19.52%，引发市场广泛关注。截至发稿时，该股报6.93港元，成交额2546.88万港元。此次股价大涨主要受三方面利好消息推动。国元国际还强调，宜明昂科-B目前市值仅为22亿港元，账上现金有7.4亿人民币，加上潜在的BD收入，公司资金充足，足以支持研发推进。随着公司业绩的持续改善和市场认可度的提升，宜明昂科-B的股价有望继续走强。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01541"],"gpt_icon":0},{"id":"2524066181","title":"港股异动 | 宜明昂科-B(01541)早盘涨超18% 全年收入同比增长192倍 机构称公司目前价值严重低估","url":"https://stock-news.laohu8.com/highlight/detail?id=2524066181","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524066181?lang=zh_cn&edition=fundamental","pubTime":"2025-04-01 10:08","pubTimestamp":1743473295,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B早盘涨近18%，截至发稿，涨18.66%，报6.93港元，成交额2546.88万港元。消息面上，宜明昂科发布度业绩，全年实现总收入7,415万元，主要来自授权许可费和合作开发收入，同比增长192倍。此外，宜明昂科-B获首席执行官田文志增持15万股H股，占公司已发行股份总数的约0.04%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1272368.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"港股异动 | 宜明昂科-B(01541)早盘涨超18% 全年收入同比增长192倍 机构称公司目前价值严重低估","news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2522804574","title":"宜明昂科-B：核心管线稳步推进 积极拓展BD合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2522804574","media":"太平洋证券","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522804574?lang=zh_cn&edition=fundamental","pubTime":"2025-03-28 00:00","pubTimestamp":1743091200,"startTime":"0","endTime":"0","summary":"事件：2025 年3 月25 日，宜明昂科发布2024 年度业绩报告，全年实现总收入7,415 万元，同比增长192 倍。目前两项III 期临床研究均处于稳步推进过程中，预计2026 年进行中期数据分析。两款双特异性抗体积极拓展BD 合作2024 年8 月公司与SynBioTx 签署授权及合作协议，将靶向PDL1/VEGF 的双特异性抗体IMM2510 在大中华地区以外的研究、开发及商业化权益授权给SynBioTx。目前IMM0306 也在积极拓展BD 合作过程中。公司核心管线临床稳步推进，数据读出后估值有望得到修复。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250328205845a4456628&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250328205845a4456628&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2522779326","title":"宜明昂科-B03月27日获主力加仓4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2522779326","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522779326?lang=zh_cn&edition=fundamental","pubTime":"2025-03-27 16:26","pubTimestamp":1743063984,"startTime":"0","endTime":"0","summary":"03月27日, 宜明昂科-B股价涨5.79%，报收5.66元，成交金额1791万元，换手率0.85%，振幅12.52%，量比1.14。宜明昂科-B今日主力资金净流入4万元，连续3日净流入，上一交易日主力净流入35万元。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为62.50%，平均涨幅为9.15%。该股近5个交易日上涨16.94%，主力资金累计净流入178万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出643万元，其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250327175731a443ce7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250327175731a443ce7c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2522593392","title":"港股异动 | 宜明昂科-B(01541)午前涨超3% 年度收入大增至7414.9万元 研发开支持续加码","url":"https://stock-news.laohu8.com/highlight/detail?id=2522593392","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522593392?lang=zh_cn&edition=fundamental","pubTime":"2025-03-27 11:36","pubTimestamp":1743046618,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B午前涨超3%，截至发稿，涨3.36%，报5.53港元，成交额716.89万港元。消息面上，近日，宜明昂科-B公布2024年业绩，收入约7414.9万元，同比增长约191.1倍；研发开支同比增加10.6%至3.23亿元。公司拥有人应占亏损约3.16亿元，同比收窄16.76%；每股亏损0.84元。公告称，收入增长主要归因于根据公司与Axion Bio, Inc.达成的授权及合作协议收取首付款及近期付款。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1268737.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"1186123918","title":"异动解读 | 宜明昂科-B盘中大涨6.17%，董事长增持15万股提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1186123918","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186123918?lang=zh_cn&edition=fundamental","pubTime":"2025-03-27 11:12","pubTimestamp":1743045150,"startTime":"0","endTime":"0","summary":"今日盘中，宜明昂科-B股价大涨6.17%，引发市场关注。这一显著涨幅很可能与公司高层近期的增持行为有关。据悉，宜明昂科-B的执行董事、首席执行官兼董事会董事长田文志于昨日（周三）在公开市场增持了15万股公司H股。增持后，田文志持有的公司股份总数达到1.16亿股，占公司已发行股本总额的28.49%。市场普遍认为，作为公司的掌舵人，田文志此次增持反映了其对公司价值的认可和对未来发展的信心，从而带动了股价的上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 宜明昂科-B盘中大涨6.17%，董事长增持15万股提振市场信心","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01541"],"gpt_icon":0},{"id":"2522395418","title":"宜明昂科(01541.HK)董事长兼CEO增持15万股  涉79万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2522395418","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522395418?lang=zh_cn&edition=fundamental","pubTime":"2025-03-27 10:17","pubTimestamp":1743041820,"startTime":"0","endTime":"0","summary":"宜明昂科-B(01541.HK) 公布，执行董事、首席执行官兼董事会董事长田文志于周三(26日)，在公开市场购买合共15万股该公司H股，每股股份平均价格约5.278元，占公司已发行股份总数约0.04%。估算涉约79.17万元。紧随购买后，田文志于合共1.16亿股股份中拥有权益，占于公司已发行股本总额28.49%。(js/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-26 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230915102623267_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230915102623267_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1428647/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2522138833","title":"宜明昂科-B(01541)获首席执行官田文志增持15万股H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2522138833","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522138833?lang=zh_cn&edition=fundamental","pubTime":"2025-03-26 22:27","pubTimestamp":1742999234,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B(01541)发布公告，该公司董事会获公司执行董事、首席执行官兼董事会董事长田文志博士告知，其已于2025年3月26日于公开市场购买合共15万股公司H股，每股股份平均价格为约5.278港元，占公司已发行股份总数的约0.04%。紧随购买后，田博士于合共1.16亿股股份中拥有权益，占于本公告日期公司已发行股本总额的28.49%。田博士表示，其对集团的整体发展前景及潜在增长充满信心。在遵守适用法律及监管规定的情况下，田博士不排除在适当时候进一步增持公司股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1268485.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"1150365699","title":"异动解读 | 宜明昂科-B盘中大跌5.17%，年度业绩亏损仍超3亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1150365699","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150365699?lang=zh_cn&edition=fundamental","pubTime":"2025-03-26 11:16","pubTimestamp":1742959004,"startTime":"0","endTime":"0","summary":"宜明昂科-B今日盘中大跌5.17%，引发市场关注。这一跌幅或与公司昨日晚间公布的2024年度业绩报告有关。根据宜明昂科发布的年度业绩公告，截至2024年12月31日，公司实现收入7414.9万元人民币，较2023年大幅增加7370万元。然而，公司仍录得3.16亿元人民币的亏损，虽较去年同期的3.79亿元有所收窄，但亏损规模依然较大。值得注意的是，宜明昂科的研发开支由2023年的2.92亿元增加至2024年的3.23亿元，增幅达10.6%。这反映了公司在新药研发方面持续加大投入。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01541"],"gpt_icon":0},{"id":"1193819091","title":"异动解读 | 宜明昂科-B盘中大涨5.17%，2024年营收暴增191倍","url":"https://stock-news.laohu8.com/highlight/detail?id=1193819091","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193819091?lang=zh_cn&edition=fundamental","pubTime":"2025-03-26 09:46","pubTimestamp":1742953593,"startTime":"0","endTime":"0","summary":"宜明昂科-B今日盘中大涨5.17%，引发市场关注。这一涨幅很可能与公司昨日发布的2024年度业绩报告密切相关。根据公告，宜明昂科-B 2024年实现营收约7414.9万元，同比大幅增长约191.1倍。值得注意的是，尽管研发支出增加，公司2024年净亏损仍同比收窄16.76%至约3.16亿元。分析人士认为，宜明昂科-B的业绩表现超出市场预期，尤其是营收的大幅增长和亏损的收窄，展现了公司业务模式的潜力和发展前景。这些积极因素可能是推动股价上涨的主要原因。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01541"],"gpt_icon":0},{"id":"2522854620","title":"宜明昂科2024年业绩：收入增至7414.9万元 年内亏损降至3.17亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2522854620","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522854620?lang=zh_cn&edition=fundamental","pubTime":"2025-03-26 09:33","pubTimestamp":1742952820,"startTime":"0","endTime":"0","summary":"3月26日，宜明昂科发布年度业绩公告，截至2024年12月31日止年度，公司的收入为7414.9万元，相较于2023年，增加了7370万元，主要由于与AxionBio, Inc.达成的授权及合作协议所产生的首付款及近期付款。此外，公司的研发开支由2023年的2.92亿元增加至2024年的3.23亿元，增幅为10.6%，主要原因是临床前及CMC开支的增加以及薪资费用的上升。公司的年内亏损由2023年的3.8亿元减少至2024年的3.17亿元，显示出一定的财务改善。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025032609341194c0f6e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025032609341194c0f6e7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01541"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/01541\",params:#limit:5,,,undefined,":[{"date":"2025-03-25","symbol":"01541","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742866200000,"name":null,"time":"盘后","dateTimestamp":1742832000000,"actualEps":null},{"market":"HK","date":"2024-08-26","symbol":"01541","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1724601600000,"reportTimeType":"post","actualEps":null},{"date":"2024-03-25","symbol":"01541","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711330200000,"name":null,"time":"","dateTimestamp":1711296000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"01541\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"01541\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1697558400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/01541\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"01541","date":"2025-05-09","current":-7.730765,"percent":0.61165,"low":-30.003263,"twenty":-24.846191,"median":-12.683619,"eighty":-5.725677,"high":-2.993766,"avg":-13.662537,"sd":8.274079,"marketCap":2623061555},"quantilePoints":[{"date":"2023-08-31","current":-17.746094,"twenty":-17.746094,"median":-17.746094,"eighty":-17.746094,"marketCap":6942262047},{"date":"2023-09-08","current":-19.116691,"twenty":-19.083294,"median":-18.655615,"eighty":-17.801139,"marketCap":7390149921},{"date":"2023-09-15","current":-24.765877,"twenty":-24.765877,"median":-19.116691,"eighty":-18.557812,"marketCap":9648251285},{"date":"2023-09-22","current":-25.548224,"twenty":-25.200205,"median":-24.360534,"eighty":-18.753419,"marketCap":9909519212},{"date":"2023-09-29","current":-29.804324,"twenty":-26.447668,"median":-24.870232,"eighty":-19.083294,"marketCap":11580180660},{"date":"2023-10-06","current":-24.76052,"twenty":-26.458287,"median":-24.870232,"eighty":-19.110012,"marketCap":9615852761},{"date":"2023-10-13","current":-27.113287,"twenty":-26.458287,"median":-25.206314,"eighty":-22.322253,"marketCap":10513831229},{"date":"2023-10-20","current":-26.768577,"twenty":-26.795293,"median":-25.37532,"eighty":-23.788881,"marketCap":10364168151},{"date":"2023-10-27","current":-28.665306,"twenty":-27.124745,"median":-25.753577,"eighty":-24.00727,"marketCap":11093775656},{"date":"2023-11-03","current":-26.275244,"twenty":-27.500238,"median":-26.158488,"eighty":-24.473108,"marketCap":10195797188},{"date":"2023-11-10","current":-26.039628,"twenty":-27.37617,"median":-26.041732,"eighty":-24.763734,"marketCap":10102257765},{"date":"2023-11-17","current":-26.714897,"twenty":-27.225983,"median":-26.171076,"eighty":-24.792429,"marketCap":10457707575},{"date":"2023-11-24","current":-27.539565,"twenty":-27.37617,"median":-26.271304,"eighty":-24.846191,"marketCap":10869281039},{"date":"2023-12-01","current":-28.464343,"twenty":-27.564693,"median":-26.306056,"eighty":-24.874164,"marketCap":11280854504},{"date":"2023-12-08","current":-27.67933,"twenty":-27.70336,"median":-26.447668,"eighty":-25.070837,"marketCap":10925404694},{"date":"2023-12-15","current":-27.708906,"twenty":-27.817253,"median":-26.526325,"eighty":-25.207536,"marketCap":11000236233},{"date":"2023-12-22","current":-27.916049,"twenty":-27.937914,"median":-26.714897,"eighty":-25.244891,"marketCap":11075067772},{"date":"2023-12-29","current":-28.049426,"twenty":-27.986303,"median":-26.835368,"eighty":-25.288293,"marketCap":11187315080},{"date":"2024-01-05","current":-23.146888,"twenty":-27.970711,"median":-26.68937,"eighty":-25.200205,"marketCap":9166863527},{"date":"2024-01-12","current":-26.439512,"twenty":-27.935571,"median":-26.500765,"eighty":-25.200205,"marketCap":10476415460},{"date":"2024-01-19","current":-25.435754,"twenty":-27.916049,"median":-26.490281,"eighty":-25.212424,"marketCap":10064841995},{"date":"2024-01-26","current":-23.636611,"twenty":-27.83997,"median":-26.442842,"eighty":-24.972615,"marketCap":9316526605},{"date":"2024-02-02","current":-21.195554,"twenty":-27.817533,"median":-26.372788,"eighty":-24.783518,"marketCap":8343716598},{"date":"2024-02-09","current":-18.727145,"twenty":-27.802108,"median":-26.275244,"eighty":-24.041989,"marketCap":7408322361},{"date":"2024-02-16","current":-17.739662,"twenty":-27.801452,"median":-26.252628,"eighty":-23.794995,"marketCap":7019198358},{"date":"2024-02-23","current":-22.387155,"twenty":-27.764049,"median":-26.165159,"eighty":-23.13759,"marketCap":8811413717},{"date":"2024-03-01","current":-17.708555,"twenty":-27.735275,"median":-26.04068,"eighty":-22.460898,"marketCap":6974299434},{"date":"2024-03-08","current":-19.229551,"twenty":-27.718352,"median":-26.025076,"eighty":-21.141323,"marketCap":7576693323},{"date":"2024-03-15","current":-16.157629,"twenty":-27.69116,"median":-25.695795,"eighty":-19.998834,"marketCap":6360680815},{"date":"2024-03-22","current":-15.411367,"twenty":-27.66021,"median":-25.548224,"eighty":-19.057216,"marketCap":6061354659},{"date":"2024-03-28","current":-14.696214,"twenty":-27.629432,"median":-25.408294,"eighty":-18.737655,"marketCap":6038905197},{"date":"2024-04-05","current":-13.011166,"twenty":-27.602384,"median":-25.364375,"eighty":-18.557812,"marketCap":5342971884},{"date":"2024-04-12","current":-13.094845,"twenty":-27.539565,"median":-25.225009,"eighty":-18.239836,"marketCap":5380387654},{"date":"2024-04-19","current":-13.014894,"twenty":-27.51439,"median":-25.154554,"eighty":-17.708555,"marketCap":5342971884},{"date":"2024-04-26","current":-13.779237,"twenty":-27.443648,"median":-24.972615,"eighty":-16.602696,"marketCap":5649781194},{"date":"2024-05-03","current":-12.839078,"twenty":-27.434442,"median":-24.870232,"eighty":-16.184677,"marketCap":5260657191},{"date":"2024-05-10","current":-13.282389,"twenty":-27.357513,"median":-24.774698,"eighty":-14.702373,"marketCap":5455219193},{"date":"2024-05-17","current":-13.228926,"twenty":-27.225983,"median":-24.581805,"eighty":-14.243189,"marketCap":5425286577},{"date":"2024-05-24","current":-13.350651,"twenty":-27.145452,"median":-23.955191,"eighty":-13.966896,"marketCap":5462702347},{"date":"2024-05-31","current":-13.410156,"twenty":-27.124745,"median":-23.750163,"eighty":-13.747349,"marketCap":5492634962},{"date":"2024-06-07","current":-14.158514,"twenty":-27.039336,"median":-23.288627,"eighty":-13.645876,"marketCap":5791961118},{"date":"2024-06-14","current":-13.347574,"twenty":-26.971042,"median":-23.123643,"eighty":-13.527845,"marketCap":5455219193},{"date":"2024-06-21","current":-13.283836,"twenty":-26.926395,"median":-22.448608,"eighty":-13.452996,"marketCap":5417803423},{"date":"2024-06-28","current":-12.683619,"twenty":-26.848726,"median":-21.974147,"eighty":-13.40419,"marketCap":5170859344},{"date":"2024-07-05","current":-11.291057,"twenty":-26.759122,"median":-21.059976,"eighty":-13.359292,"marketCap":4602139648},{"date":"2024-07-12","current":-12.246119,"twenty":-26.720023,"median":-20.206581,"eighty":-13.323498,"marketCap":4998746805},{"date":"2024-07-19","current":-11.915911,"twenty":-26.704686,"median":-19.229551,"eighty":-13.282563,"marketCap":4864050035},{"date":"2024-07-26","current":-11.780484,"twenty":-26.652155,"median":-19.050696,"eighty":-13.224977,"marketCap":4826634265},{"date":"2024-08-02","current":-13.633124,"twenty":-26.594701,"median":-18.753419,"eighty":-13.20236,"marketCap":5582432809},{"date":"2024-08-09","current":-9.567144,"twenty":-26.54166,"median":-18.630761,"eighty":-13.102374,"marketCap":3943622105},{"date":"2024-08-16","current":-8.483685,"twenty":-26.496571,"median":-18.451463,"eighty":-13.086665,"marketCap":3498374448},{"date":"2024-08-23","current":-8.095604,"twenty":-26.47337,"median":-18.020488,"eighty":-13.035717,"marketCap":3352452947},{"date":"2024-08-30","current":-7.377309,"twenty":-26.446703,"median":-17.739662,"eighty":-12.990136,"marketCap":3034418906},{"date":"2024-09-06","current":-4.227864,"twenty":-26.442176,"median":-17.681919,"eighty":-12.840212,"marketCap":1739833281},{"date":"2024-09-13","current":-4.503325,"twenty":-26.43833,"median":-16.602696,"eighty":-12.741292,"marketCap":1848339013},{"date":"2024-09-20","current":-4.539912,"twenty":-26.433601,"median":-16.202037,"eighty":-12.246119,"marketCap":1874530051},{"date":"2024-09-27","current":-5.476578,"twenty":-26.311976,"median":-15.844451,"eighty":-11.915911,"marketCap":2274878785},{"date":"2024-10-04","current":-6.596451,"twenty":-26.302504,"median":-15.05764,"eighty":-11.832338,"marketCap":2727609596},{"date":"2024-10-10","current":-5.983695,"twenty":-26.285201,"median":-14.496802,"eighty":-11.807116,"marketCap":2458216056},{"date":"2024-10-18","current":-5.191078,"twenty":-26.27288,"median":-14.209972,"eighty":-11.719903,"marketCap":2121474130},{"date":"2024-10-25","current":-7.104995,"twenty":-26.248892,"median":-14.119017,"eighty":-11.287262,"marketCap":2903463713},{"date":"2024-11-01","current":-6.615271,"twenty":-26.199776,"median":-13.881638,"eighty":-9.764235,"marketCap":2705160134},{"date":"2024-11-08","current":-6.847628,"twenty":-26.169892,"median":-13.803075,"eighty":-8.441853,"marketCap":2787474827},{"date":"2024-11-15","current":-7.078843,"twenty":-26.118271,"median":-13.690467,"eighty":-8.248986,"marketCap":2851081635},{"date":"2024-11-22","current":-6.784782,"twenty":-26.059844,"median":-13.633178,"eighty":-7.853303,"marketCap":2731351173},{"date":"2024-11-29","current":-5.682581,"twenty":-26.04047,"median":-13.539989,"eighty":-7.45767,"marketCap":2286103516},{"date":"2024-12-06","current":-5.602773,"twenty":-26.037499,"median":-13.514674,"eighty":-7.358253,"marketCap":2248687746},{"date":"2024-12-13","current":-6.121403,"twenty":-26.029477,"median":-13.45004,"eighty":-7.218028,"marketCap":2451992323},{"date":"2024-12-20","current":-5.137492,"twenty":-25.962318,"median":-13.411134,"eighty":-7.087735,"marketCap":2048757705},{"date":"2024-12-27","current":-4.957491,"twenty":-25.887099,"median":-13.400213,"eighty":-7.078006,"marketCap":1975442320},{"date":"2025-01-03","current":-5.238569,"twenty":-25.753577,"median":-13.368079,"eighty":-6.925822,"marketCap":2089488475},{"date":"2025-01-10","current":-5.002231,"twenty":-25.638014,"median":-13.3526,"eighty":-6.765934,"marketCap":1987661551},{"date":"2025-01-17","current":-5.018682,"twenty":-25.5579,"median":-13.317479,"eighty":-6.665777,"marketCap":1995807705},{"date":"2025-01-24","current":-5.323319,"twenty":-25.548224,"median":-13.283546,"eighty":-6.596451,"marketCap":2130219244},{"date":"2025-01-28","current":-5.224689,"twenty":-25.503236,"median":-13.282823,"eighty":-6.532117,"marketCap":2101707706},{"date":"2025-02-07","current":-5.549725,"twenty":-25.42477,"median":-13.246663,"eighty":-6.254752,"marketCap":2219826937},{"date":"2025-02-14","current":-5.930475,"twenty":-25.395104,"median":-13.220128,"eighty":-6.076947,"marketCap":2366457707},{"date":"2025-02-21","current":-6.375256,"twenty":-25.366564,"median":-13.201126,"eighty":-6.054191,"marketCap":2557892324},{"date":"2025-02-28","current":-5.632443,"twenty":-25.318672,"median":-13.116805,"eighty":-5.974648,"marketCap":2252411553},{"date":"2025-03-07","current":-5.782376,"twenty":-25.249925,"median":-13.099044,"eighty":-5.827424,"marketCap":2321653861},{"date":"2025-03-14","current":-4.421401,"twenty":-25.219975,"median":-13.087912,"eighty":-5.725677,"marketCap":1775861550},{"date":"2025-03-21","current":-4.778207,"twenty":-25.207536,"median":-13.071662,"eighty":-5.66584,"marketCap":1918419243},{"date":"2025-03-28","current":-6.735516,"twenty":-25.163684,"median":-13.026305,"eighty":-5.651503,"marketCap":2276850015},{"date":"2025-04-03","current":-7.956153,"twenty":-25.0977,"median":-13.01303,"eighty":-5.66026,"marketCap":2684157710},{"date":"2025-04-11","current":-6.344288,"twenty":-25.036833,"median":-12.972072,"eighty":-5.68428,"marketCap":2126146167},{"date":"2025-04-17","current":-6.122985,"twenty":-24.972615,"median":-12.844749,"eighty":-5.691075,"marketCap":2056903859},{"date":"2025-04-25","current":-8.576896,"twenty":-24.895951,"median":-12.836736,"eighty":-5.703559,"marketCap":2883738480},{"date":"2025-05-02","current":-7.700417,"twenty":-24.872853,"median":-12.82514,"eighty":-5.710649,"marketCap":2594550017},{"date":"2025-05-09","current":-7.730765,"twenty":-24.846191,"median":-12.683619,"eighty":-5.725677,"marketCap":2623061555}],"updateTime":1746884099598}}}